Historical Valuation
CorMedix Inc (CRMD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.95 is considered Undervalued compared with the five-year average of -4.73. The fair price of CorMedix Inc (CRMD) is between 16382.81 to 16392.01 according to relative valuation methord. Compared to the current price of 7.51 USD , CorMedix Inc is Undervalued By 99.95%.
Relative Value
Fair Zone
16382.81-16392.01
Current Price：7.51
99.95%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
CorMedix Inc (CRMD) has a current Price-to-Book (P/B) ratio of 2.55. Compared to its 3-year average P/B ratio of 5.01 , the current P/B ratio is approximately -49.17% higher. Relative to its 5-year average P/B ratio of 4.37, the current P/B ratio is about -41.79% higher. CorMedix Inc (CRMD) has a Forward Free Cash Flow (FCF) yield of approximately 7.77%. Compared to its 3-year average FCF yield of -10.60%, the current FCF yield is approximately -173.29% lower. Relative to its 5-year average FCF yield of -11.34% , the current FCF yield is about -168.53% lower.
P/B
Median3y
5.01
Median5y
4.37
FCF Yield
Median3y
-10.60
Median5y
-11.34
Competitors Valuation Multiple
AI Analysis for CRMD
The average P/S ratio for CRMD competitors is 18524.91, providing a benchmark for relative valuation. CorMedix Inc Corp (CRMD.O) exhibits a P/S ratio of 1.95, which is -99.99% above the industry average. Given its robust revenue growth of 810.22%, this premium appears sustainable.
Performance Decomposition
AI Analysis for CRMD
1Y
3Y
5Y
Market capitalization of CRMD increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CRMD in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CRMD currently overvalued or undervalued?
CorMedix Inc (CRMD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.95 is considered Undervalued compared with the five-year average of -4.73. The fair price of CorMedix Inc (CRMD) is between 16382.81 to 16392.01 according to relative valuation methord. Compared to the current price of 7.51 USD , CorMedix Inc is Undervalued By 99.95% .
What is CorMedix Inc (CRMD) fair value?
CRMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of CorMedix Inc (CRMD) is between 16382.81 to 16392.01 according to relative valuation methord.
How does CRMD's valuation metrics compare to the industry average?
The average P/S ratio for CRMD's competitors is 18524.91, providing a benchmark for relative valuation. CorMedix Inc Corp (CRMD) exhibits a P/S ratio of 1.95, which is -99.99% above the industry average. Given its robust revenue growth of 810.22%, this premium appears sustainable.
What is the current P/B ratio for CorMedix Inc (CRMD) as of Jan 09 2026?
As of Jan 09 2026, CorMedix Inc (CRMD) has a P/B ratio of 2.55. This indicates that the market values CRMD at 2.55 times its book value.
What is the current FCF Yield for CorMedix Inc (CRMD) as of Jan 09 2026?
As of Jan 09 2026, CorMedix Inc (CRMD) has a FCF Yield of 7.77%. This means that for every dollar of CorMedix Inc’s market capitalization, the company generates 7.77 cents in free cash flow.
What is the current Forward P/E ratio for CorMedix Inc (CRMD) as of Jan 09 2026?
As of Jan 09 2026, CorMedix Inc (CRMD) has a Forward P/E ratio of 4.34. This means the market is willing to pay $4.34 for every dollar of CorMedix Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for CorMedix Inc (CRMD) as of Jan 09 2026?
As of Jan 09 2026, CorMedix Inc (CRMD) has a Forward P/S ratio of 1.95. This means the market is valuing CRMD at $1.95 for every dollar of expected revenue over the next 12 months.